Retatrutide cuts weight 22.5 kg at 80 weeks in TRIUMPH-2 diabetes trial
About six in 10 participants on the 12 mg dose no longer met the BMI threshold for obesity by the end of the 80-week study.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 29 18:01 ETSource: Scientific American
The wire
- 01In TRIUMPH-2, 1,152 people with obesity and type 2 diabetes lost an average of 13.5 kg on 4 mg, 20.6 kg on 9 mg and 22.5 kg on 12 mg of retatrutide versus 4.2 kg on placebo, Eli Lilly said.
- 02Retatrutide is the first GLP-1/GIP/glucagon triple agonist to report phase 3 results, and participants also saw lower blood sugar, cholesterol and blood pressure.
- 03Between 28.4% and 40% of retatrutide patients reached normalized blood sugar depending on dose; findings were published in the Lancet, with regulatory review still ahead.
From the source
Read at scientificamerican.comBlockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugs
Blockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugs
